Anesthesia, Asthma
Conditions
Keywords
Dexmedetomidine, Inflammatory factor, Inflammatory mediator, Cytokines, Asthma
Brief summary
The study try to illustrate the possible mechanisms of tending to induce airway spasms and the impact of dexmedetomidine on inflammatory reaction in general anesthesia patients with asthma，by detecting the differences of plasma inflammatory factor interleukin(IL)-4, IL-5, IL-13, IL-17, IL-33, MBP and immunoglobulin E(IgE) levels between asthma patients and non-asthma patients.
Interventions
DRUGAnesthesia induction
-Intravenous injection midazolam 0.05 mg/Kg,fentanyl 4μg/Kg,etomidate 0.2 mg/Kg,cisatracurium 0.15 mg/Kg in proper order.
* Continuous intravenous remifentanil O.2μg/(kg•h) and propofol 3\ 8mg/(kg•h). * Intermittent intravenous atracurium 0.05mg/kg. Maintain partial pressure of carbon dioxide(PETCO2) to 30\ 40 mmHg and bispectral index (BIS) to 45\ 60.
DRUGAssisted anesthesia
Intervention 'Assisted anesthesia' has been included in Arm Descriptions.
Sponsors
Second Affiliated Hospital of Xi'an Jiaotong University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Obtain informed consent * Elective general anesthesia surgery, surgery time 1 \ 3 hours. * 20 patients with a history of asthma. * 60 patients with no history of asthma. * American Society of Anesthesiologists (ASA)classification:class I\ II. * Aged between 18 and 65 years old.
Exclusion criteria
* SBP≥180 mmHg or \<90 mmHg, DBP≥110 mmHg or \<60 mmHg. * Serious heart, brain, liver, kidney, lung, endocrine diseases or serious infections. * Hematopoietic dysfunction or bleeding tendency and hemorrhagic disease. * A neuromuscular system disease. * Airway and lung surgery. * Predict possible or happened difficult airway. * Immune function defect. * Sure/suspected abuse of narcotic analgesics or drugs or alcohol dependence. * The test drug allergy or have other contraindications in patients. * Childbearing age women not to take appropriate contraception, pregnancy or lactation. * Participated in other clinical drug research in the last 30 days.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| IL-4，IL-5，IL-13, IL-17, IL-33 concentration in the Plasma | enter the operation room(T0)、10min after intubation(T1)、 skin incision(T2)、the end of surgery(T3)、24H after surgery(T4) |
| Histamine concentration | enter the operation room(T0)、10min after intubation(T1)、 skin incision(T2)、the end of surgery(T3)、24H after surgery(T4) |
| Myelin Basic Protein concentration （MBP) | enter the operation room(T0)、10min after intubation(T1)、 skin incision(T2)、the end of surgery(T3)、24H after surgery(T4) |
| IgE concentration | enter the operation room(T0)、10min after intubation(T1)、 skin incision(T2)、the end of surgery(T3)、24H after surgery(T4) |
Secondary
| Measure | Time frame |
|---|---|
| Heart rate（HR） | enter the operation room(T0)、10min after intubation(T1)、 skin incision(T2)、the end of surgery(T3)、24H after surgery(T4) |
| Respiratory rate（RR） | enter the operation room(T0)、10min after intubation(T1)、 skin incision(T2)、the end of surgery(T3)、24H after surgery(T4) |
| Mean arterial pressure（MAP） | enter the operation room(T0)、10min after intubation(T1)、 skin incision(T2)、the end of surgery(T3)、24H after surgery(T4) |
Outcome results
None listed